5-叔-丁氧基间二甲苯 | 68856-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 5-叔-丁氧基间二甲苯
• 英文名称: 1-tert-butoxy-3,5-dimethylbenzene
• 英文别名: 5-tert-butoxy-m-xylene；Benzene, 1-(1,1-dimethylethoxy)-3,5-dimethyl-；1,3-dimethyl-5-[(2-methylpropan-2-yl)oxy]benzene
• CAS: 68856-26-8
• 化学式: C₁₂H₁₈O
• 分子量: 178.274
• InChiKey: FOMVFPYJDBUIFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异丁烯 、 3,5-二甲基苯酚 在 硫酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 以1.9 g的产率得到5-叔-丁氧基间二甲苯
  参考文献：
  名称：

  Olefin Hydroaryloxylation Catalyzed by Pincer–Iridium Complexes

  摘要：

  Aryl alkyl ethers, which are widely used throughout the chemical industry, are typically produced via the Williamson ether synthesis. Olefin hydroaryloxylation potentially offers a much more atom-economical alternative. Known acidic catalysts for hydroaryloxylation, however, afford very poor selectivity. We report the organometallic-catalyzed intermolecular hydroaryloxylation of unactivated olefins by iridium "pincer" complexes. These catalysts do not operate via the hidden Bronsted acid pathway common to previously developed transition-metal-based catalysts. The reaction is proposed to proceed via olefin insertion into an iridium-alkoxide bond, followed by rate-determining C-H reductive elimination to yield the ether product. The reaction is highly chemo- and regioselective and offers a new approach to the atom-economical synthesis of industrially important ethers and, potentially, a wide range of other oxygenates.

  DOI：

  10.1021/ja404566v

文献信息

• [EN] METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE LA MÉTHYLAMINE COMME INHIBITEURS DE LA LYSYL OXIDASE POUR LE TRAITEMENT DU CANCER
  申请人：THE INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

  公开号：WO2017141049A1

  公开（公告）日：2017-08-24

  Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.

  提供的是Formula (I)的化合物，或其药用可接受的盐，其中W、X、Y、Z、x、R1、R2、R3、x和n在规范中有定义。这些化合物是赖氨酸氧化酶（LOX）和赖氨酸氧化酶样（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）的抑制剂，并且在治疗中很有用，特别是在癌症治疗中。还披露了用于治疗与EGFR相关的癌症的LOX抑制剂，以及预测对LOX抑制剂响应性的生物标志物。
• COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR AND LIQUID CRYSTAL DISPLAY DEVICE
  申请人：KANNA Shinichi

  公开号：US20110217636A1

  公开（公告）日：2011-09-08

  The present invention provides a colored curable composition including a phthalocyanine pigment, a dioxazine pigment, a dye, a polymerization initiator, a polymerizable compound and a solvent; and a colored curable composition including a phthalocyanine pigment, a dye multimer having a polymerizable group and a group derived from a dipyrromethene dye, a polymerization initiator, a polymerizable compound and a solvent.

  本发明提供了一种彩色可固化组合物，包括酞菁颜料、二氧化锰颜料、染料、聚合引发剂、可聚合化合物和溶剂；以及一种彩色可固化组合物，包括酞菁颜料、具有可聚合基团和源自二吡咯甲烷染料的染料多聚物、聚合引发剂、可聚合化合物和溶剂。
• RORGamma Modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150266856A1

  公开（公告）日：2015-09-24

  Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R a , x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.

  本文描述了公式（I）的RORy调节剂及其N-氧化物、药学上可接受的盐、溶剂和水合物，其中R1、R2、R3、R4、R5、R6、Ra、x、y、L、G、Z、“q”表示的键、表示的环系统“A”和表示的环系统“B”在此定义。还提供了包含这些化合物的制药组合物。这些化合物和组合物在调节细胞中的RORy活性的方法和治疗患有疾病或障碍的受试者中是有用的，其中该受试者在调节RORy活性方面具有治疗益处，例如自身免疫和/或炎症性疾病。
• A Simple and Powerful tert-Butylation of Carboxylic Acids and Alcohols
  作者：Kosuke Namba、Chie Ogasa、Kimika Kayano

  DOI：10.1055/a-2161-9689

  日期：2024.1

  A simple and safe tert-butylation reaction was developed. Treatment of various free amino acids with 1.1 equivalents of bis(trifluoromethanesulfonyl)imide in tert-butyl acetate directly afforded tert-butyl esters with free amino groups quickly and in good yields. In addition, various carboxylic acids and alcohols without amino groups were converted into tert-butyl esters and ethers, respectively, in

  开发了一种简单且安全的叔丁基化反应。用1.1当量的双(三氟甲磺酰基)亚胺的乙酸叔丁酯溶液处理各种游离氨基酸，可以快速且高收率地直接得到具有游离氨基的叔丁酯。此外，在少量催化量的双(三氟甲磺酰基)亚胺存在下，各种不含氨基的羧酸和醇分别以高产率转化为叔丁基酯和醚。与传统方法相比，游离氨基酸、羧酸和醇的所有叔丁基化反应进行得更快并且产率更高。
• RORγ modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10035790B2

  公开（公告）日：2018-07-31

  Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.

  描述了式 (I) 的 RORy 调节剂、其 N-氧化物、其药学上可接受的盐、其溶液和水合物，其中 R1、R2、R3、R4、R5、R6、Ra、x、y、L、G、Z、用 "q "表示的键、用 "A "表示的环系和用 "B "表示的环系在本文中定义。此外，还提供了包含这些化合物的药物组合物。此类化合物和组合物可用于调节细胞中 RORy 活性的方法和治疗患有疾病或失调的受试者的方法，其中受试者将从调节 RORy 活性中获得治疗上的益处，例如自身免疫和/或炎症性失调。